Literature DB >> 8608235

Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection.

S Imai1, M Sugiura, O Oikawa, S Koizumi, M Hirao, H Kimura, H Hayashibara, N Terai, H Tsutsumi, T Oda, S Chiba, T Osato.   

Abstract

Four novel Epstein-Barr virus (EBV)-carrying T-cell lines, designated SIS, AIK-T8, AIK-T4, and SKN, were established from peripheral blood lymphocytes (PBL) of patients with severe chronic active EBV infection, in the presence of interleukin-2 and 4-deoxyphorbol ester. AIK-T8 and -T4 were derived from a single patient. Cell marker and genotype analyses showed that SIS, AIK-T8, and AIK-T4 had mature T-cell phenotypes with clonally rearranged T-cell receptor (TCR) genes, whereas SKN had an immature T-cell phenotype without TCR gene rearrangement. None of the cell lines expressed B, natural killer, or myeloid antigens or had Ig gene rearrangement. All lines carried EBV genomes in a single episomal form. SIS, AIK-T8, and SKN showed the same phenotype, TCR gene configuration, and/or EBV clonotype as their source or biopsied materials; therefore, they represented EBV-infected T cells proliferating in the patients. TCR gene and EBV episomal structures similar to those of AIK-T4 were not found in its source PBL, probably due to the few parental clones in vivo. All lines expressed EBV-encoded small RNA (EBER) 1, nuclear antigen (EBNA) 1, and latent membrane protein (LMP) 1, -2A, and -2B, but not other EBNAs that could be recognized by EBV-specific immune T cells. EBV replicative antigens were rarely expressed or induced. Such EBV latency reflects the in vivo situation, in which the T cells may evade immune surveillance and be insensitive to antiherpesvirus drugs. Collectively, the data suggest that EBV can target and latently infect T cells at any stage of differentiation in vivo, thus potentially causing uncontrolled T-cell proliferation. These cell lines will facilitate further analyses of possible EBV-induced oncogenicity in T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608235

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Efficient Isolation Protocol for B and T Lymphocytes from Human Palatine Tonsils.

Authors:  Farzaneh Assadian; Karl Sandström; Göran Laurell; Catharina Svensson; Göran Akusjärvi; Tanel Punga
Journal:  J Vis Exp       Date:  2015-11-16       Impact factor: 1.355

2.  Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.

Authors:  Jeffrey I Cohen; Lesia Dropulic; Amy P Hsu; Christa S Zerbe; Tammy Krogmann; Kennichi Dowdell; Ronald L Hornung; Jana Lovell; Nancy Hardy; Dennis Hickstein; Edward W Cowen; Katherine R Calvo; Stefania Pittaluga; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079

3.  Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.

Authors:  S Imai; J Nishikawa; K Takada
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line.

Authors:  I Tsuge; T Morishima; M Morita; H Kimura; K Kuzushima; H Matsuoka
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

5.  Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Michiko K Oyoshi; Hiroshi Nagata; Nobuhiro Kimura; Yu Zhang; Ayako Demachi; Toshiro Hara; Hirokazu Kanegane; Yoshinobu Matsuo; Tomohiro Yamaguchi; Tomohiro Morio; Atsuyoshi Hirano; Norio Shimizu; Kohtaro Yamamoto
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

6.  Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.

Authors:  Masanori Daibata; Kentaro Bandobashi; Masayuki Kuroda; Shosuke Imai; Isao Miyoshi; Hirokuni Taguchi
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease--report of three cases.

Authors:  B Hügle; P Suchowerskyj; H Hellebrand; B Adler; M Borte; U Sack; U Schulte Overberg-Schmidt; N Strnad; J Otto; A Meindl; V Schuster
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

8.  Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection.

Authors:  Masao Hagihara; Takahide Tsuchiya; Osamu Hyodo; Yoko Ueda; Kei Tazume; Aya Masui; Ayako Kanemura; Fumiaki Yoshiba; Shinji Takashimizu; Shohei Matzusaki; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.